ATE425160T1 - Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen - Google Patents

Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen

Info

Publication number
ATE425160T1
ATE425160T1 AT03814019T AT03814019T ATE425160T1 AT E425160 T1 ATE425160 T1 AT E425160T1 AT 03814019 T AT03814019 T AT 03814019T AT 03814019 T AT03814019 T AT 03814019T AT E425160 T1 ATE425160 T1 AT E425160T1
Authority
AT
Austria
Prior art keywords
protein kinase
kinase inhibitors
compounds
benzisoxazole derivatives
pharmaceutically acceptable
Prior art date
Application number
AT03814019T
Other languages
English (en)
Inventor
Mark Ledeboer
Robert Davies
David Messersmith
Young-Choon Moon
Michael Mullican
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE425160T1 publication Critical patent/ATE425160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT03814019T 2002-12-18 2003-12-17 Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen ATE425160T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43488002P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
ATE425160T1 true ATE425160T1 (de) 2009-03-15

Family

ID=32682120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814019T ATE425160T1 (de) 2002-12-18 2003-12-17 Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen

Country Status (6)

Country Link
US (1) US7226919B2 (de)
EP (1) EP1581526B1 (de)
AT (1) ATE425160T1 (de)
AU (1) AU2003297160A1 (de)
DE (1) DE60326646D1 (de)
WO (1) WO2004058749A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2006020145A2 (en) * 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
MX2007014619A (es) * 2005-05-20 2009-02-13 Vertex Pharma Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
GB0510922D0 (en) * 2005-05-27 2005-07-06 Fond Ct San Rafaelle Del Monte Hsi
EP3002330A1 (de) 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Genvektor
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
MX2008001538A (es) * 2005-08-02 2008-04-04 Lexicon Pharmaceuticals Inc Aril piridinas y metodos para su uso.
CA2626623C (en) 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5331681B2 (ja) 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
WO2008049123A2 (en) 2006-10-19 2008-04-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2008082840A1 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2008343173A1 (en) 2007-12-19 2009-07-09 Aj Park Pyrazolo [1,5-a] pyrimidines useful as JAK2 inhibitors
NZ587589A (en) 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
EP2271631B1 (de) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitoren von proteinkinasen
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2521782B1 (de) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale FLT3-Rezeptorantagonisten zur Behandlung oder Vorbeugung von Schmerzstörungen
SG182480A1 (en) 2010-01-12 2012-08-30 Ab Science Thiazole and oxazole kinase inhibitors
EP2635557A2 (de) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamide als jak-kinasemodulatoren
EP2662078A1 (de) * 2010-11-10 2013-11-13 National Jewish Health Verfahren zur Behandlung von allergischen Zuständen
WO2012154274A1 (en) 2011-02-25 2012-11-15 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012143144A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
IN2014CN04065A (de) 2011-11-23 2015-09-04 Portola Pharm Inc
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (de) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Verfahren zur herstellung heterocyclischer esterderivate
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
JP2015529242A (ja) 2012-09-21 2015-10-05 アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 置換された縮合三環式化合物、組成物およびその医薬用途
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
CN107200749B (zh) 2013-03-12 2019-09-03 沃泰克斯药物股份有限公司 Dna-pk抑制剂
EP3057953B1 (de) 2013-10-17 2018-08-15 Vertex Pharmaceuticals Incorporated Co-kristalle von (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)chinolin-4-carboxamid und deuterierten derivaten davon als dna-pk-hemmer
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US10065937B2 (en) 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
EP3254698A1 (de) 2016-06-08 2017-12-13 Universite De Montpellier Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
WO2018085292A1 (en) 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
CA2376951A1 (en) * 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
MY133159A (en) 1999-08-13 2007-10-31 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1274705A1 (de) * 2000-03-29 2003-01-15 Cyclacel Limited 2-substituierte 4-heteroaryl-pyrimidine und ihre verwendung zur behandlung von proliferativen erkrankungen
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors

Also Published As

Publication number Publication date
EP1581526B1 (de) 2009-03-11
WO2004058749A1 (en) 2004-07-15
DE60326646D1 (de) 2009-04-23
AU2003297160A1 (en) 2004-07-22
EP1581526A1 (de) 2005-10-05
US7226919B2 (en) 2007-06-05
US20040186115A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
ATE425160T1 (de) Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
ATE466581T1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MXPA05012596A (es) Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol.
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
DE60106409D1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties